ClinVar

Description

This variant is denoted MSH2 c.1831G>C at the cDNA level, p.Val611Leu (V611L) at the protein level, and results in the change of a Valine to a Leucine (GTG>CTG). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. MSH2 Val611Leu was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Valine and Leucine share similar properties, this is considered a conservative amino acid substitution. MSH2 Val611Leu occurs at a position where amino acids with properties similar to Valine are tolerated across species and is located within a region of interaction with EXO1, MSH3, and MSH6 as well as within the Lever domain (Guerrette 1998, Lutzen 2008, Kansikas 2011). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether MSH2 Val611Leu is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.